Skip to main content
. 2021 Jun 30;22(13):7049. doi: 10.3390/ijms22137049

Figure 1.

Figure 1

Paralogous 13 HOX proteins expression in GEP-NEN tumor categories: (a) NETG1 with Ki67 expression <3% (×20); (b) NETG2 with Ki67 expression between 3–20%; (c) NETG3 with Ki67 expression >20%; (d) NECG3 with Ki67 expression >20%; (e) positive HOXA13 nuclear expression in NETG1 (×20); (f) positive HOXA13 nuclear expression in NETG2 (×20); (g) negative HOXA13 expression NETG3 (×20); (h) positive HOXA13 nuclear expression in NECG3 (×20); (i) negative HOXB13 in NETG1 (×20); (l) negative HOXB13 in NETG2 (×20); (m) positive HOXB13 cytoplasm expression NETG3 (×20); (n) positive HOXB13 nuclear expression in NECG3 (×20); (o) positive HOXC13 nuclear and cytoplasm expression in NETG1 (×20); (p) positive HOXC13 nuclear expression in NETG2 (×20); (q) positive HOXC13 nuclear expression in NETG3 (×20); (r) negative HOXC13 expression in NEC G3(x20); (s) positive HOXD13 nuclear and cytoplasm expression in NETG1 (×20); (t) positive HOXD13 nuclear expression in NETG2 (×20); (u) positive HOXD13 nuclear and cytoplasm expression in NETG3 (×20); (v) negative HOXD13 expression in NECG3 (×20).